drugset / Trial / NCT01273844
Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)
Completed
21 enrolled
Zhi-Hong Liu, M.D.
Nanjing Medical University · collabSoochow University · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of Vel-Dex therapy (bortezomib and dexamethasone) followed by autologous hematopoietic stem cell transplantation as an initial treatment in patients with newly diagnosed AL.
Timeline
- Start
- 2011-03-01
- Primary completion
- 2016-05-12
- Completion
- 2016-05-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.6 mg/m2 | Intravenous |